Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection
Open Access
- 1 July 2010
- journal article
- review article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 6 (1) , 455-464
Abstract
Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. Risperidone long acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA) in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.Keywords
This publication has 49 references indexed in Scilit:
- Antipsychotic long-acting injections: Mind the gapThe British Journal of Psychiatry, 2009
- [Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder].2009
- Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.2008
- Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)Journal of Affective Disorders, 2008
- Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patientsHuman Psychopharmacology: Clinical and Experimental, 2007
- A 6‐month randomized open‐label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorderActa Psychiatrica Scandinavica, 2007
- Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorderProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2007
- Risperidone plasma levels, clinical response and side–effectsEuropean Archives of Psychiatry and Clinical Neuroscience, 2004
- Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to ratsPsychopharmacology, 2002
- Guidelines for depot antipsychotic treatment in schizophreniaEuropean Neuropsychopharmacology, 1998